Thus, the therapeutic relevance of FTY720 in COVID-19 is complex, probably due to its antagonistic effect on S1PR1 leading to the degradation of this receptor and inhibition of S1PR1-mediated vascular protection, while it can still enhance the EC barrier via a novel S1PR1-independent mechanism [88,92]. This evidence concerns the gene S1PR1 and COVID-19.